• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, August 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home Headlines

New medication significantly decreases involuntary movement

Bioengineer.org by Bioengineer.org
January 20, 2018
in Headlines, Health, Science News
Reading Time: 1 min read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: University of South Florida

Tampa, FL (April 7, 2017) Antipsychotic treatment can cause involuntary movements such as lip smacking, tongue protrusions and excessive eye blinking. These movements typically occur after more than 3 months of treatment and are called tardive dyskinesia.

Robert A. Hauser, MD, MBA, professor of neurology at the University of South Florida in Tampa, is the lead author of a study published in the American Journal of Psychiatry that concludes valbenazine administered once daily can significantly reduce tardive dyskinesia in patients with schizophrenia, schizoaffective disorder and mood disorder.

"One approach to managing tardive dyskinesia is to discontinue antipsychotic treatment or reduce the dosage, but these options are not always feasible, because withdrawal can exacerbate tardive dyskinesia symptoms or have a negative impact on psychiatric status. Moreover, tardive dyskinesia symptoms often persist even after discontinuation or dosage reduction," wrote Dr. Hauser, who directs the Parkinson's Disease and Movement Disorders Center at USF.

Valbenazine is a selective vesicular monoamine transporter 2 inhibitor. Two hundred twenty-five people with schizophrenia, schizoaffective disorder or a mood disorder participated in the phase 3 randomized double blind, placebo-controlled trial.

Forty-percent of those who received valbenazine 80mg/day improved by at least 50 percent. That's compared to just 8 percent in the placebo group.

Researchers also determined that valbenazine was well tolerated. Drowsiness, restlessness and dry mouth were reported as adverse effects.

###

Media Contact

Tina Meketa
[email protected]
813-955-2593

http://www.hsc.usf.edu

Share12Tweet8Share2ShareShareShare2

Related Posts

Chronic Kidney Disease in Women: Global Burden and Metabolic-Cardiovascular Connections

August 19, 2026
Molecular Self-Assembly Enables High-Throughput DNA Fragment Synthesis from Overlapping Oligonucleotides

Molecular Self-Assembly Enables High-Throughput DNA Fragment Synthesis from Overlapping Oligonucleotides

August 19, 2026

Dynamic duo weaves hierarchical DNA materials using two classes of biomolecular nanomachines

August 19, 2026

Wiley Launches First Spectral Analysis API Portfolio to Speed Substance Identification

August 19, 2026
Please login to join discussion

POPULAR NEWS

  • Chronic Kidney Disease in Women: Global Burden and Metabolic-Cardiovascular Connections

    29 shares
    Share 12 Tweet 7
  • Molecular Self-Assembly Enables High-Throughput DNA Fragment Synthesis from Overlapping Oligonucleotides

    29 shares
    Share 12 Tweet 7
  • Dynamic duo weaves hierarchical DNA materials using two classes of biomolecular nanomachines

    29 shares
    Share 12 Tweet 7
  • Wiley Launches First Spectral Analysis API Portfolio to Speed Substance Identification

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Chronic Kidney Disease in Women: Global Burden and Metabolic-Cardiovascular Connections

Molecular Self-Assembly Enables High-Throughput DNA Fragment Synthesis from Overlapping Oligonucleotides

Dynamic duo weaves hierarchical DNA materials using two classes of biomolecular nanomachines

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.